

Single shot versus continuous technique adductor canal block for analgesia following total knee arthroplasty

A PRISMA-compliant meta-analysis

Lu-kai Zhang, MD^{a,*}, Bo-ya Zhang, MD^{b,c}, Ren-fu Quan, MD^a, Hong Xu, MD^a, Yu-jie Sun, MD^c, Jian-hong Zhou, MD^c

Abstract

Background: An adductor canal block (ACB) provides recognized analgesia following total knee arthroplasty (TKA). This metaanalysis compared the single-injection ACB (SACB) with the continuous-injection ACB (CACB).

Method: Relevant studies were searched from PubMed (1996–October 2018), Embase (1980–October 2018), and Cochrane Library (CENTRAL, October 2018). Four randomized controlled trials (RCTs), which compared SACB with CACB, were included in our meta-analysis.

Results: Four RCTs met the inclusion criteria. Our pooled data indicated that the SACB group had similar efficacy compared with the CACB group in terms of morphine consumption (P = .19), time to first opioid request (P = .32), range of motion (P = .97), and visual analogue scale (VAS) scores at 24 hours at rest (P = .12) and movement (P = .24), without increasing the risk of complications (P = .97) and length of stay (P = .54).

Conclusion: The SACB technique provides similar analgesia in the 24 hours following TKA compared with CACB, while the CACB method was better over 48 hours.

Abbreviations: BMI = body mass index, CACB = continuous-injection adductor canal block, CIs = confidence intervals, DVT = deep vein thrombosis, LOS = length of hospital stay, MD = mean difference, OR = odds ratio, PE = pulmonary embolism, PONV = postoperative nausea and vomiting, PRISMA = Preferred Reporting Items for Systematic Review and Meta-analyses, RCT = randomized controlled trial, RD = risk difference, ROM = range of motion, RR = relative risk, SACB = single-injection adductor canal block, TKA = total knee arthroplasty, VAS = visual analogue scale.

Keywords: adductor canal block, continuous, meta-analysis, single shot, total knee arthroplasty

1. Introduction

Total knee arthroplasty (TKA) is a common surgical procedure for a painful arthritic knee. It has been reported that the number of TKA procedures will reach 3.48 million by 2030.^[1,2]

Editor: Yan Li.

L-kZ and B-yZ contributed equally to this work.

The authors report no conflicts of interest.

^a Department of Orthopaedics, Xiaoshan Traditional Chinese Medical Hospital, Hangzhou, Zhejiang Province, ^b School of Integrative Medicine of Tianjin University of Traditional Chinese Medicine, ^c Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China.

^{*} Correspondence: Lu-kai Zhang, Xiaoshan Traditional Chinese Medical Hospital, No. 156, Yucai Road, Xiaoshan District, Zhejiang 311200, People's Republic of China (e-mail: zlk_919@163.com).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Medicine (2019) 98:20(e15539)

Received: 26 November 2018 / Received in final form: 6 March 2019 / Accepted: 9 April 2019

http://dx.doi.org/10.1097/MD.000000000015539

However, TKA is followed by moderate to severe pain during the postoperative period.^[3] Adequate pain relief following TKA can promote early rehabilitation. Patient-controlled analgesia (PCA) and epidural analgesia are the conventional analgesia methods,^[4–7] and the femoral nerve block (FNB) is recognized as the gold standard for pain relief following TKA.^[8,9] On the contrary, FNB adds the risk of reducing quadriceps muscle strength, thus compromising postoperative rehabilitation.^[10]

The adductor canal block (ACB), one kind of peripheral nerve block (PNB), is increasingly being used.^[11–13] Several published studies have demonstrated the superiority of the ACB in analgesic effect as compared to FNB.^[14,15] There is a growing consensus that the ACB should be recommended as the analgesic choice for patients undergoing TKA.^[16,17] However, there is no consensus as to which is better between the single-shot adductor canal and the continuous adductor canal blockade.

Thus, we performed the first meta-analysis to compare the efficacy of the continuous ACB (CACB) and the single-shot ACB (SACB).

2. Method and materials

Our meta-analysis was conducted by the Cochrane Handbook for systematic review of interventions (Review Manager 5.3). The

study was approved by the ethics committee of Xiaoshan Traditional Chinese Medical Hospital.

2.1. Search strategy

We systematically searched PubMed (1996–October 2018), Embase (1980–October 2018), and the Cochrane Library (CENTRAL, October 2018). We also searched related references and Google Scholar. Only randomized controlled trials (RCTs) were included in our meta-analysis. "Total knee arthroplasty," "Total knee replacement," "ACB," "Adductor canal block" were the key words used with Boolean operators "AND" or "OR." The search results are shown in Fig. 1.

2.2. Inclusion criteria

RCTs were included in our meta-analysis if they met the following PICOS (patients, intervention, comparator, outcome, study design) criteria:

- (1) Patients: patients had received TKA for the first time.
- (2) Intervention: Patients received a single-shot ACB for TKA.
- (3) Comparator: Patients received a continuous ACB for TKA.
- (4) Outcomes: morphine consumption, VAS score at rest and movement, time to first opioid request, range of motion (ROM), complications, and LOS.
- (5) Study design: RCTs.

2.3. Data extraction and bias risk assessment

Two reviewers independently collected available data from studies, and any disagreement between the 2 reviewers was judged by a third reviewer. Basic characteristics include patients' age, gender, body mass index (BMI), and reference type. The morphine consumption and VAS score were primary outcomes in our meta-analysis. All opioids were converted to equivalent morphine consumption dosage according to the standard formula.^[18] The VAS score consists of 11 pain levels with 0 being no pain and 10 representing the worst pain. Secondary outcomes consisted of time to first opioid request, ROM, complications, and length of stay (LOS). We emailed corresponding authors to obtain any incomplete data. We chose the *Cochrane Handbook* for systematic review of interventions (Review Manager 5.3) to evaluate the risk bias of the included studies.

2.4. Statistical analysis

We used Review Manager 5.3 software (Cochrane Collaboration, Copenhagen: The Nordic Cochrane Centre) for our metaanalysis. For continuous data, the mean difference (MD) with 95% confidence interval (95% CI) was applied to weigh the effect interval. For noncontinuous data, the risk ratio (RR) and risk differences (RDs) with 95% CIs were used to figure the effect interval. *P* and I^2 were used to assess the statistical heterogeneity among the included studies. When $I^2 < 50\%$ and P > .1, we



The characteris	tics of included	studies.				
			SACB Group/CACB Gro	oup		
Ref.	Patients	Age, y	Female gender (%)	BMI, kg/m ²	ASA (I/II/III)	Reference type
Turner et al ^[19]	30/30	68.8/70.9	30/57	31.3/31.5	N/A	RCT
Li et al ^[21]	30/30	67.7/65.9	80/80	24.2/25.2	0/23/7/0/25/5	RCT
Lee et al ^[20]	60/57	67/65.6	62/58	31.3/29.9	N/A	RCT
Shah et al ^[22]	39/46	66.3/68.3	82.1/71.7	30.2/29.6	14/23/2/12/32/2	RCT

ASA=American Society of Anesthesiologists, BMI=body mass index, CACB=continuous adductor canal block, N/A=not applicable, RCT=randomized controlled trial, SACB=single-shot adductor canal block.

applied a fixed-effects model; otherwise, a random-effect model was applied.

3. Results

Table 1

3.1. Search results

According to our search strategy, a total of 88 studies were found. Ten studies were excluded by Endnote software, and 66 studies were removed after reading the title and abstract. Of the original 88, 4 RCTs^[19–22] were included in our meta-analysis. The basic characteristics and interventions are summarized in Tables 1 and 2.

3.2. Risk of bias of assessment

The risk of bias of assessment of RCTs is presented in Figs. 2 and 3. Among the 4 RCTs, 2 studies^[20,22] were recorded using computer-generated randomization or a web-based randomization service. Two RCTs reported allocation concealment via sealed envelopes or other methods.^[19,21] A double-blind method was applied by Turner et al.^[19] The publication bias was assessed using a funnel plot diagram (Fig. 4).

3.3. Results of meta-analysis

3.3.1. Morphine consumption. Two studies, including 176 patients, reported morphine consumption for postoperative day 1, and no significant differences were found between the 2 groups

(MD = -5.25; 95% CI, -13.53 to 3.02; P = .21, Fig. 5). A similar finding was found for postoperative day 2 (MD = -3.04; 95% CI, -14.98 to 8.90; P = .62, Fig. 5). Due to no significant heterogeneity in morphine consumption for day 1 ($x^2 = 1.09$; df = 1; P = .30; $I^2 = 8\%$, Fig. 5) or day 2 ($x^2 = 1.47$; df = 1; P = .23; $I^2 = 32\%$, Fig. 5), a fixed-effects model was applied.

3.3.2. VAS score at rest. Four studies consisting of 321 patients reported VAS scores at rest at postoperative 12 hours, and no significant differences were found between the 2 groups (MD= 0.25; 95% CI, -0.44 to 0.95; P=.47, Fig. 6). Data from 4 studies, including 321 patients, compared the VAS scores at rest at postoperative 24 hours. No significant differences were found between the 2 groups (MD=0.39; 95% CI, -0.10 to 0.88; P=.12, Fig. 6). The VAS scores at rest at postoperative 48 hours were reported in 4 studies containing 321 patients. The SACB group had higher scores than the CACB group (MD=0.90; 95% CI, 0.28–1.53; P < .05, Fig. 6). Due to significant heterogeneity in VAS scores at rest at postoperative 12 hours (x²=10.60; df=3; P < .05; I^2 =72%, Fig. 6), a random-effects model was applied.

3.3.3. VAS score at movement. Two studies reported VAS scores at movement at postoperative 12 hours, and the SACB group had higher scores than the CACB group (MD = 1.04; 95% CI, 0.24–1.85; P < .05, Fig. 7). A similar finding was found at postoperative 48 hours (MD = 1.03; 95% CI, 0.57–1.49; P = .62, Fig. 7). Three studies consisting of 204 patients reported the VAS

Table 2

Characteristics of included studies showing general intervention information.

	Analgesics	and dosage			
Ref.	SACB Group	/CACB Group	Surgical approach	Anesthesia	Pneumatic tourniquet
Turner et al ^[19]	20 mL of 0.25% bupivacaine, 1.67 µg/mL clonidine, 150 µg of buprenorphine, 2 mg dexamethasone, 2.5 µg/mL of epinephrine.	20 mL of 0.25% bupivacaine and 2.5 μg/mL of epinephrine, and continuous infusion of 0.125% bupivacaine (8 mL/h)	N/A	Spinal anesthetic or a general anesthetic	N/A
Li et al ^[21]	30 mL of 2.5 g/L ropivacaine, 0.1 mg epinephrine	30 mL of 2.5 g/L ropivacaine, 0.1 mg epinephrine, 8 mL/h 2.5 g/L ropivacaine	Medial parapatellar arthrotomy	General anesthesia	Use
Lee et al ^[20]	20 mL of 0.5% ropivacaine	20 mL of 0.5% ropivacaine, 0.2% ropivacaine at 5 mL/h for 48 h	N/A	Spinal anesthesia	N/A
Shah et al ^[22]	30 mL of 0.75% ropivacaine	30 mL of 0.75% ropivacaine, 30 mL 0.25% ropivacaine at an interval of 4 h	Minisubvastus approach	Spinal anesthesia	None

CACB = continuous adductor canal block, N/A = not applicable, SACB = single-shot adductor canal block.



Figure 2. The risk of bias summary: review authors' judgment of each risk of bias items for each included studies.

scores in movement at postoperative 24 hours, while we were unable to find any significant differences between the 2 groups (MD = 0.45; 95% CI, -0.30 to 1.20; P=.24, Fig. 7). We used a random-effects model because of the significant heterogeneity in VAS scores in movement at postoperative 24 hours (x^2 =7.04; df=2; P=.03; I^2 =72%, Fig. 7) and 48 hours (x^2 =4.20; df=2; P=.12; I^2 =52%, Fig. 7).

3.3.4. Time to first opioid request (hours). Two studies consisting of 176 patients reported the time to first opioid request (hours), and no significant differences were found between the 2 groups (MD=0.31; 95% CI, -0.30 to 0.93; P=.32, Fig. 8). We used a fixed-effects model, as no significant



Figure 3. The risk of bias graph of the included studies.

heterogeneity was found between the SACB and CACB groups ($x^2=0.23$; df=1; P=.63; $I^2=0\%$, Fig. 8).

3.3.5. Range of motion. ROM was reported in 2 studies consisting of 145 patients. No significant differences were found between the SACB and CACB groups (MD=0.06; 95% CI, -2.76 to 2.88; P=.97, Fig. 9). We used a fixed-effects model because no significant heterogeneity was found ($x^2=0.02$; df=1; P=.89; $I^2=0\%$, Fig. 9).

3.3.6. Complications. Three studies reported postoperative nausea and vomiting (PONV) in the SACB and CACB groups, and no significant differences were found between the 2 groups (RD = -0.03; 95% CI, -0.11 to 0.05; P = .51, Fig. 10). Data from 3 studies consisting of 262 patients reported the incidence of deep venous thrombosis (DVT). No significant differences were found between the 2 groups (RD = 0; 95% CI, -0.03 to 0.03; P = 1, Fig. 10). We used a fixed-effects model because no significant heterogeneity was found in PONV ($x^2 = 3.85$; df = 2; P = .15; $I^2 = 48\%$, Fig. 10) and DVT ($x^2 = 0$; df = 2; P = 1; $I^2 = 0\%$, Fig. 10).

3.3.7. LOS. Then, LOS was reported in 4 studies with a total of 321 patients. Our pooled data indicated that the SACB group had similar LOS compared with the CACB group (MD=0.12; 95% CI, -0.02 to 0.25; P=.09, Fig. 11). We used a random-effects model for heterogeneity between the included studies (x²=6.09; df=3; P=.11; I^2 =51%, Fig. 11).

4. Discussion

This study, to the best of our knowledge, is the first meta-analysis comparing the SACB and CACB methods. The results of our meta-analysis demonstrated that the SACB technique provides similar analgesia in the 24 hours following TKA when compared with the ACB, while the CACB was better over 48 hours.

Appropriate pain management following TKA can lower postoperative pain and promote early rehabilitation.^[23,24] Postoperative analgesia is usually managed by a PNB and a FNB. The FNB is recognized as the gold standard for pain relief following TKA. Alternatives to the FNB include epidural analgesia, periarticular infiltration analgesia, and an ACB.^[24,25] In our previous study,^[7] we found that local infiltration analgesia has similar analgesic properties to the FNB. Recently published studies^[19,20] have reported that the ACB has equivalent analgesia efficacy as compared with the FNB method. However, it is not clear which method is better between the SACB and the CACB.

Morphine consumption was the primary outcome in our metaanalysis. Morphine consumption is one of most important indexes to estimate the efficacy of analgesia methods. Shah et al^[22] found that compared with the SACB method, the CACB has better efficacy in terms of pain control, but was similar for early functional recovery. Some other recently published studies have different opinions. An RCT conducted by Lee et al^[20] found that at 24 and 48 hours, the SACB was equal to the CACB for opioid consumption. Turner et al^[19] also reported that there were no significant differences found between the SACB and the CACB groups related to opioid consumption at either 36 or 48 hours. Our meta-analysis results also indicated that the SACB had similar morphine consumption when compared with the CACB group within 48 hours postoperative. Thus, we draw a conclusion that the SACB group had the same morphine consumption as the CACB group.



Figure 4. (A) A funnel plot of morphine consumption (mg); (B) A funnel plot of VAS at rest; (C) A funnel plot of VAS at movement; (D) A funnel plot of time to first opioid request (hours); (E) A funnel plot of range of motion; (F) A funnel plot of Complications; (G) A funnel plot of LOS.

In this meta-analysis, we used a VAS score to weigh the analgesia effect. We found that the SACB group was equal to the CACB group within 24 hours. Turner et al^[19] also reported that numerical rating scale (NRS) pain score comparisons were not

statistically different between the 2 groups with 42 hours postoperative (rest, P=.01; movement, P=.25) and 48 hours (rest, P=.001; movement, P=.04). Similar findings were reported by Shah et al.^[22]

	5	SACB		0	CACB			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV. Fixed, 95% CI
1.1.2 At 24 hours									
Lee et al 2017	50.5	26.7	60	60.2	37.1	57	33.4%	-9.70 [-21.46, 2.06]	
Turner et al 2018	28.6	24.7	30	29.5	20.8	29	34.1%	-0.90 [-12.54, 10.74]	
Subtotal (95% CI)			90			86	67.6%	-5.25 [-13.53, 3.02]	•
Heterogeneity: Chi ² =	1.09, df	= 1 (P	= 0.30	; 12 = 89	6				
Test for overall effect:	Z = 1.24	(P=(0.21)						
1.1.3 At 48 hours									
Lee et al 2017	61.5	46.2	60	71	41.3	57	18.4%	-9.50 [-25.36, 6.36]	
Turner et al 2018	48.4	42.2	30	43	27.6	29	14.1%	5.40 [-12.74, 23.54]	
Subtotal (95% CI)			90			86	32.4%	-3.04 [-14.98, 8.90]	-
Heterogeneity: Chi ² =	1.47, df	= 1 (P	= 0.23	; l ² = 32	2%				
Test for overall effect:	Z = 0.50	(P = (0.62)						
Total (95% CI)			180			172	100.0%	-4.54 [-11.34, 2.27]	•
Heterogeneity: Chi ² = 2	2.64, df	= 3 (P	= 0.45	; l ² = 09	6			2014 - 00 - 67-1 g .	
Test for overall effect:	Z = 1.31	(P = (0.19)						-50 -25 0 25 50
Test for subaroup diffe	rences:	Chi ² =	0.09. 0	if = 1 (P	= 0.7	7), ² =	0%		Favours [SACE] Favours [CACE]
	Fi	igure	5. A fo	prest pla	ot diag	gram s	howing th	ne equivalent morphine	consumption (mg).

ROM was used to measure early mobilization. It is well-known that early mobilization can facilitate functional recovery and reduce postoperative complications and length of hospital stay. Shah et al^[22] used a large hospital database to assess the data of ROM among both the SACB and CACB groups. The results of the RCT demonstrated that the ROM at discharge and length of hospital stay displayed almost identical results with no statistical

significance (106.5 vs 106.4, 3.08 vs 3.20, P > .05, respectively). Li et al^[21] also reported that there was no statistical significance toward ROM between the SACB and CACB groups at discharge (101.8±9.5 vs 101.5±8, P > .05, respectively). Taking these findings together, the SACB achieved similar effects for ROM and LOS when compared with the CACB in patients undergoing TKA. With regard to time to first opioid request, Turner et al^[19]

	5	SACB		c	CACB			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
2.1.1 At 12 hours									
Lee et al 2017	3	2.7	60	4	2.7	57	4.8%	-1.00 [-1.98, -0.02]	
Li et al 2017	3.6	1.55	30	2.77	1.36	30	7.1%	0.83 [0.09, 1.57]	
Shah et al 2015	2.7	0.5	39	2.1	0.57	46	16.7%	0.60 [0.37, 0.83]	-
Turner et al 2018	2.1	2.8	30	1.9	2.6	29	2.7%	0.20 [-1.18, 1.58]	
Subtotal (95% CI)			159			162	31.2%	0.25 [-0.44, 0.95]	-
Heterogeneity: Tau ² =	0.32; Ch	ni² = 10	.60, df	= 3 (P =	= 0.01	; l ² = 7:	2%		
Test for overall effect:	Z = 0.72	(P=0	.47)						
2.1.2 At 24 hours									
Lee et al 2017	3	1.5	60	3	1.5	57	10.0%	0.00 [-0.54, 0.54]	
Li et al 2017	4.1	1.67	30	3.07	1.34	30	6.7%	1.03 [0.26, 1.80]	
Shah et al 2015	2.7	0.44	39	2.1	0.43	46	17.5%	0.60 [0.41, 0.79]	-
Turner et al 2018	2.3	2.3	30	2.8	2.3	29	3.6%	-0.50 [-1.67, 0.67]	
Subtotal (95% CI)			159			162	37.8%	0.39 [-0.10, 0.88]	•
Heterogeneity: Tau ² =	0 15 CH	$i^2 = 8$	70 46-	0 /0 -	0 001	12 - 000	A (
Test for overall effect:	Z = 1.56	(P=0).12)	: 3 (P =	0.03);	1- = 66	%		
Test for overall effect: . 2.1.3 At 48 hours	Z = 1.56	i (P = (78, df =).12)	3 (P =	0.03);	1- = 00	%		
Test for overall effect: . 2.1.3 At 48 hours Lee et al 2017	Z = 1.56	5.39	60 60	3 (P = 3	5.39	57	% 1.5%	-1.00 [-2.95, 0.95]	
Test for overall effect: . 2.1.3 At 48 hours Lee et al 2017 Li et al 2017	Z = 1.56 2 3.43	5.39 1.5	60 30	3 (P = 3 2.53	5.39 1.41	57 30	% 1.5% 7.1%	-1.00 [-2.95, 0.95] 0.90 [0.16, 1.64]	
Test for overall effect: 2.1.3 At 48 hours Lee et al 2017 Li et al 2017 Shah et al 2015	Z = 1.56 2 3.43 2.3	5.39 1.5 0.3	60 30 39	3 (P = 3 2.53 1.5	5.39 1.41 0.3	57 30 46	% 1.5% 7.1% 18.5%	-1.00 [-2.95, 0.95] 0.90 [0.16, 1.64] 0.80 [0.67, 0.93]	
Test for overall effect: 2.1.3 At 48 hours Lee et al 2017 Li et al 2017 Shah et al 2015 Turner et al 2018	Z = 1.56 2 3.43 2.3 3.9	5.39 1.5 0.3 2.4	60 30 39 30	3 (P = 3 2.53 1.5 1.9	5.39 1.41 0.3 1.9	57 30 46 29	% 1.5% 7.1% 18.5% 3.9%	-1.00 [-2.95, 0.95] 0.90 [0.16, 1.64] 0.80 [0.67, 0.93] 2.00 [0.90, 3.10]	
Test for overall effect: 2.1.3 At 48 hours Lee et al 2017 Li et al 2017 Shah et al 2015 Turner et al 2018 Subtotal (95% CI)	Z = 1.56 2 3.43 2.3 3.9	5.39 1.5 0.3 2.4	60 30 39 30 159	3 (P = 2.53 1.5 1.9	5.39 1.41 0.3 1.9	57 30 46 29 162	% 1.5% 7.1% 18.5% 3.9% 31.0%	-1.00 [-2.95, 0.95] 0.90 [0.16, 1.64] 0.80 [0.67, 0.93] 2.00 [0.90, 3.10] 0.90 [0.28, 1.53]	
Test for overall effect: 2.1.3 At 48 hours Lee et al 2017 Li et al 2017 Shah et al 2015 Turner et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² =	Z = 1.56 2 3.43 2.3 3.9 0.22; Ch	5.39 1.5 0.3 2.4 hi ² = 7.	60 30 39 30 159 85, df =	3 2.53 1.5 1.9 : 3 (P =	5.39 1.41 0.3 1.9 0.05);	57 30 46 29 162 ² = 62'	% 1.5% 7.1% 18.5% 3.9% 31.0% %	-1.00 [-2.95, 0.95] 0.90 [0.16, 1.64] 0.80 [0.67, 0.93] 2.00 [0.90, 3.10] 0.90 [0.28, 1.53]	
Test for overall effect: 2.1.3 At 48 hours Lee et al 2017 Li et al 2017 Shah et al 2015 Turner et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect:	Z = 1.56 2 3.43 2.3 3.9 0.22; Cr Z = 2.83	5.39 5.39 1.5 0.3 2.4 $hi^{2} = 7.4$ $6 (P = 0)$	60 30 39 30 159 85, df =	3 2.53 1.5 1.9 3 (P =	5.39 1.41 0.3 1.9 0.05);	57 30 46 29 162 ² = 62 ¹	% 1.5% 7.1% 18.5% 3.9% 31.0% %	-1.00 [-2.95, 0.95] 0.90 [0.16, 1.64] 0.80 [0.67, 0.93] 2.00 [0.90, 3.10] 0.90 [0.28, 1.53]	
Test for overall effect: 2.1.3 At 48 hours Lee et al 2017 Li et al 2017 Shah et al 2015 Turner et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1 Total (95% CI)	2 = 1.56 2 3.43 2.3 3.9 0.22; Cr Z = 2.83	5.39 1.5 0.3 2.4 $hi^2 = 7.3$ i (P = 0)	60 30 39 30 159 85, df = 0.005)	3 2.53 1.5 1.9 3 (P =	5.39 1.41 0.3 1.9 0.05);	57 30 46 29 162 ² = 62 ¹ 486	% 1.5% 7.1% 18.5% 3.9% 31.0% %	-1.00 [-2.95, 0.95] 0.90 [0.16, 1.64] 0.80 [0.67, 0.93] 2.00 [0.90, 3.10] 0.90 [0.28, 1.53]	
Test for overall effect: 2.1.3 At 48 hours Lee et al 2017 Li et al 2017 Shah et al 2015 Turner et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: Total (95% CI) Heterogeneity: Tau ² =	2 = 1.56 2 3.43 2.3 3.9 0.22; Cr Z = 2.83	5.39 5.39 1.5 0.3 2.4 $hi^{2} = 7.4$ $F = 0$ $hi^{2} = 35$	60 30 39 30 159 85, df = 0.005) 477 5.88, df	3 2.53 1.5 1.9 3 (P =	5.39 1.41 0.3 1.9 0.05);	57 30 46 29 162 1 ² = 62 ¹ 486 002); 1 ²	% 1.5% 7.1% 18.5% 3.9% 31.0% % 100.0% = 69%	-1.00 [-2.95, 0.95] 0.90 [0.16, 1.64] 0.80 [0.67, 0.93] 2.00 [0.90, 3.10] 0.90 [0.28, 1.53]	
Test for overall effect: 2.1.3 At 48 hours Lee et al 2017 Li et al 2017 Shah et al 2015 Turner et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = Total (95% CI) Heterogeneity: Tau ² = Total (95% CI)	Z = 1.56 2 3.43 2.3 3.9 0.22; Cr Z = 2.83 0.08; Cr Z = 4.39	5.39 1.5 0.3 2.4 $hi^2 = 7.4$ $hi^2 = 35$ (P = 0)	60 30 39 30 159 85, df = 0.005) 477 5.88, df	3 (P = 2.53 1.5 1.9 3 (P = = 11 (P	5.39 1.41 0.3 1.9 0.05);	57 30 46 29 162 1 ² = 62 ¹ 486 002); 1 ²	% 1.5% 7.1% 18.5% 3.9% 31.0% % 100.0% = 69%	-1.00 [-2.95, 0.95] 0.90 [0.16, 1.64] 0.80 [0.67, 0.93] 2.00 [0.90, 3.10] 0.90 [0.28, 1.53] 0.55 [0.30, 0.79]	-2 -1 0 1 2 Favours [SACR] Favours [CACR]

		SACB		(CACB			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV. Random. 95% CI
3.1.1 At 12 hours									
Li et al 2017	4.57	1.43	30	3.3	1.39	30	8.5%	1.27 [0.56, 1.98]	
Turner et al 2018	3.5	3.1	30	3.2	3	29	2.1%	0.30 [-1.26, 1.86]	
Subtotal (95% CI)			60			59	10.6%	1.04 [0.24, 1.85]	◆
Heterogeneity: Tau ² =	0.09; C	hi² = 1.	.23, df =	= 1 (P =	0.27);	l ² = 19	%		
Test for overall effect:	Z = 2.53	3 (P =)	0.01)						
3.1.2 At 24 hours									
Li et al 2017	5.17	1.37	30	5.17	1.37	30	8.9%	0.00 [-0.69, 0.69]	+
Shah et al 2015	3.6	0.45	39	2.7	0.42	46	31.5%	0.90 [0.71, 1.09]	
Turner et al 2018	5.1	3.3	30	5.1	3.1	29	2.0%	0.00 [-1.63, 1.63]	
Subtotal (95% CI)			99			105	42.3%	0.45 [-0.30, 1.20]	-
Heterogeneity: Tau ² =	0.29; C	hi² = 7.	.04, df =	= 2 (P =	0.03);	l ² = 72	%		
Test for overall effect:	Z = 1.16	6 (P =)	0.24)						
3.1.3 At 48 hours									
Li et al 2017	4.67	1.03	30	3.5	1.23	30	11.7%	1.17 [0.60, 1.74]	
Shah et al 2015	3	0.46	39	2.2	0.3	46	32.7%	0.80 [0.63, 0.97]	
Turner et al 2018	6.8	2.6	30	4.8	2.8	29	2.7%	2.00 [0.62, 3.38]	the second se
Subtotal (95% CI)			99			105	47.1%	1.03 [0.57, 1.49]	•
Heterogeneity: Tau ² =	0.09; C	hi² = 4.	.20, df =	= 2 (P =	0.12);	$ ^2 = 52$	%		
Test for overall effect:	Z = 4.39	9 (P <)	0.0001)		1000				
Total (95% CI)			258			269	100.0%	0.85 [0.62, 1.08]	•
Heterogeneity: Tau ² =	0.04; C	hi² = 13	3.10, df	= 7 (P	= 0.07); $ ^2 = 4$	7%		
Test for overall effect:	Z = 7.10) (P <)	0.00001)					
Test for subaroup diffe	erences:	Chi ² =	1.84. 0	if = 2 (F	= 0.4	0). I ² =	0%		Favours [SACB] Favours [CACB]
			Fig	ire 7	A fore	st nlot	diagram	showing the VAS at mo	vement



	S	SACB		c	CACB			Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Fixed, 95% CI	IV. Fixed, 95% CI	
Li et al 2017	101.8	9.5	30	101.5	8	30	40.4%	0.30 [-4.14, 4.74]		
Shah et al 2015	106.4	8.42	39	106.5	8.74	46	59.6%	-0.10 [-3.76, 3.56]		
Total (95% CI)			69			76	100.0%	0.06 [-2.76, 2.88]	-	
Heterogeneity: Chi ² =	0.02, df	= 1 (P	= 0.89)	; 12 = 09	6					-
Test for overall effect:	Z = 0.04	(P = (0.97)						Favours [CACB] Favours [SACB]	

found that in the SACB group versus the CACB group, time to first analgesic administration was 869 versus 754.5 minutes, P=.57. Similar findings were reported by Lee et al.^[20] Postoperative PONV was a common complication in TKA. Our meta-analysis failed to find any significant differences between the SACB and CACB groups. Similar findings were reported by Li et al^[21] and Turner et al.^[19] Lee et al^[20] reported that no occurrences of catheter site infections were found in their

study. Shah et al^[22] also reported that none of the patients in either group showed any other side effects or treatment-related complications. Therefore, the SACB method was found to be a suitable method for pain relief for patients undergoing TKA.

Our systematic review and meta-analysis has several limitations. First, only 4 RCTs were included in our meta-analysis. Pooled data would be more accurate and reliable if more RCTs had been included. Second, we evaluated only the VAS score

	SACE	3	SAC	в		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H. Fixed, 95% CI
6.1.1 Nausea and vor	niting						
Li et al 2017	5	30	3	30	12.9%	0.07 [-0.10, 0.24]	
Shah et al 2015	1	39	1	46	18.1%	0.00 [-0.06, 0.07]	
Turner et al 2018	4	30	9	30	12.9%	-0.17 [-0.37, 0.04]	
Subtotal (95% CI)		99		106	43.9%	-0.03 [-0.11, 0.05]	-
Total events	10		13				
Heterogeneity: Chi ² = 3	3.85, df = 2	(P = 0)).15); l ² =	48%			
Test for overall effect:	Z = 0.66 (P	= 0.5	1)				
6.1.2 DVT							
Lee et al 2017	0	60	0	57	25.1%	0.00 [-0.03, 0.03]	-+-
Li et al 2017	0	30	0	30	12.9%	0.00 [-0.06, 0.06]	
Shah et al 2015	0	39	0	46	18.1%	0.00 [-0.05, 0.05]	- <u>+</u> -
Subtotal (95% CI)		129		133	56.1%	0.00 [-0.03, 0.03]	•
Total events	0		0				
Heterogeneity: Chi ² = 0	0.00, df = 2	(P = 1	1.00); l ² =	0%			
Test for overall effect:	Z = 0.00 (P	= 1.0	0)				
Total (95% CI)		228		239	100.0%	-0.01 [-0.05, 0.03]	•
Total events	10		13				
Heterogeneity: Chi ² = 4	4.20, df = 5	(P = 0).52); l ² =	0%		11 .	
Test for overall effect:	Z = 0.61 (P	= 0.5	4)				-0.2 -0.1 0 0.1 0.2
Test for subgroup diffe	erences: Ch	i ² = 0.3	39. df = 1	(P = 0	53), l² = 0	%	Favours [SACE] Favours [CACE]
		F	igure 10.	A fore	st plot dia	gram showing the com	plications.



within 48 hours after TKA. Therefore, a long-term follow-up study would be more persuasive. Third, outcomes such as quadriceps muscle strength and total duration of analgesia failed to be analyzed due to insufficient data. Finally, the PRISMA guidelines and *Cochrane Handbook*^[26] were used in our meta-analysis to ensure the quality of our meta-analysis.

5. Conclusion

Overall, our meta-analysis results demonstrated that compared with the CACB method, the SACB may be more preferable, particularly for hospitals without experienced anesthesiologists and resources to perform the continuous infusions.

Author contributions

Conceptualization: Jian-hong Zhou. Data curation: Bo-ya Zhang, Ren_fu Quan. Formal analysis: Bo-ya Zhang. Investigation: Bo-ya Zhang, Hong Xu. Methodology: Yu-jie Sun. Resources: Yu-jie Sun.

Software: Hong Xu, Yu-jie Sun.

Supervision: Yu-jie Sun.

Validation: Jian-hong Zhou.

Visualization: Jian-hong Zhou.

Writing - original draft: Jian-hong Zhou.

Writing - review & editing: Lu-kai Zhang, Ren_fu Quan, Jianhong Zhou.

References

- Cram P, Lu X, Kates SL, et al. Total knee arthroplasty volume, utilization, and outcomes among Medicare beneficiaries, 1991–2010. JAMA 2012;308:1227–36.
- [2] Kurtz S, Ong K, Lau E, et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007;89:780–5.
- [3] Puolakka PA, Rorarius MG, Roviola M, et al. Persistent pain following knee arthroplasty. Eur J Anaesthesiol 2010;27:455–60.
- [4] Gomez-Cardero P, Rodriguez-Merchan EC. Postoperative analgesia in TKA: ropivacaine continuous intraarticular infusion. Clin Orthop Relat Res 2010;468:1242–7.

- [5] Kazak Bengisun Z, Aysu Salviz E, Darcin K, et al. Intraarticular levobupivacaine or bupivacaine administration decreases pain scores and provides a better recovery after total knee arthroplasty. J Anesth 2010;24:694–9.
- [6] Safa B, Gollish J, Haslam L, et al. Comparing the effects of single shot sciatic nerve block versus posterior capsule local anesthetic infiltration on analgesia and functional outcome after total knee arthroplasty: a prospective, randomized, double-blinded, controlled trial. J Arthroplasty 2014;29:1149–53.
- [7] Zhang LK, Ma JX, Kuang MJ, et al. Comparison of periarticular local infiltration analgesia with femoral nerve block for total knee arthroplasty: a meta-analysis of randomized controlled trials. J Arthroplasty 2018;33:1972–8. e1974.
- [8] Basques BA, Tetreault MW, Della Valle CJ. Same-day discharge compared with inpatient hospitalization following hip and knee arthroplasty. J Bone Joint Surg Am 2017;99:1969–77.
- [9] Salinas FV, Liu SS, Mulroy MF. The effect of single-injection femoral nerve block versus continuous femoral nerve block after total knee arthroplasty on hospital length of stay and long-term functional recovery within an established clinical pathway. Anesth Analg 2006;102:1234–9.
- [10] Elkassabany NM, Antosh S, Ahmed M, et al. The risk of falls after total knee arthroplasty with the use of a femoral nerve block versus an adductor canal block: a double-blinded randomized controlled study. Anesth Analg 2016;122:1696–703.
- [11] Grevstad U, Mathiesen O, Valentiner LS, et al. Effect of adductor canal block versus femoral nerve block on quadriceps strength, mobilization, and pain after total knee arthroplasty: a randomized, blinded study. Reg Anesth Pain Med 2015;40:3–10.
- [12] Mariano ER, Perlas A. Adductor canal block for total knee arthroplasty: the perfect recipe or just one ingredient? Anesthesiology 2014;120:530– 2.
- [13] Memtsoudis SG, Yoo D, Stundner O, et al. Subsartorial adductor canal vs femoral nerve block for analgesia after total knee replacement. Int Orthop 2015;39:673–80.
- [14] Jaeger P, Zaric D, Fomsgaard JS, et al. Adductor canal block versus femoral nerve block for analgesia after total knee arthroplasty: a randomized, double-blind study. Reg Anesth Pain Med 2013;38:526–32.
- [15] Zhao XQ, Jiang N, Yuan FF, et al. The comparison of adductor canal block with femoral nerve block following total knee

arthroplasty: a systematic review with meta-analysis. J Anesth 2016;30:745-54.

- [16] Andersen LO, Gaarn-Larsen L, Kristensen BB, et al. Subacute pain and function after fast-track hip and knee arthroplasty. Anaesthesia 2009;64:508–13.
- [17] Webb CA, Mariano ER. Best multimodal analgesic protocol for total knee arthroplasty. Pain Manag 2015;5:185–96.
- [18] Chaumeron A, Audy D, Drolet P, et al. Periarticular injection in knee arthroplasty improves quadriceps function. Clin Orthop Relat Res 2013;471:2284–95.
- [19] Turner JD, Dobson SW, Henshaw DS, et al. Single-injection adductor canal block with multiple adjuvants provides equivalent analgesia when compared with continuous adductor canal blockade for primary total knee arthroplasty: a double-blinded, randomized, controlled, equivalency trial. J Arthroplasty 2018;33:3160–6.e1.
- [20] Lee S, Rooban N, Vaghadia H, et al. A randomized non-inferiority trial of adductor canal block for analgesia after total knee arthroplasty: single injection versus catheter technique. J Arthroplasty 2018;33:1045–51.
- [21] Li C, Xu H, Shen B, et al. [Effect of continuous and single shot adductor canal blocks for postoperative analgesia and early rehabilitation after total knee arthroplasty]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2017;31:1049–54.
- [22] Shah NA, Jain NP, Panchal KA. Adductor canal blockade following total knee arthroplasty-continuous or single shot technique? Role in postoperative analgesia, ambulation ability and early functional recovery: a randomized controlled trial. J Arthroplasty 2015;30:1476–81.
- [23] Parvataneni HK, Shah VP, Howard H, et al. Controlling pain after total hip and knee arthroplasty using a multimodal protocol with local periarticular injections: a prospective randomized study. J Arthroplasty 2007;22(6 suppl 2):33–8.
- [24] Duellman TJ, Gaffigan C, Milbrandt JC, et al. Multi-modal, pre-emptive analgesia decreases the length of hospital stay following total joint arthroplasty. Orthopedics 2009;32:167.
- [25] Kerr DR, Kohan L. Local infiltration analgesia: a technique for the control of acute postoperative pain following knee and hip surgery: a case study of 325 patients. Acta Orthop 2008;79:174–83.
- [26] Green S. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Naunyn-Schmiedebergs Archiv f
 ür experimentelle Pathologie und Pharmakologie. 2011;5(2):S38.